Related Experiment Video

Updated: Feb 18, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

6.7K

Effects of L- and N-Type Ca Channel Blocker Cilnidipine on Changes in Heart Rate and QT Interval During Dialysis

Takeshi Iida1,2, Satoshi Morimoto1, Yoshifumi Amari1,2

  • 1Department of Medicine II, Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.

Kidney & Blood Pressure Research
|November 23, 2017
PubMed

Insights

Cilnidipine, a calcium channel blocker, effectively reduced heart rate and QT prolongation during hemodialysis compared to amlodipine. This suggests cilnidipine may lower cardiovascular event risk in dialysis patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Hemodialysis patients face high cardiovascular disease risks.
  • Increased sympathetic nerve activity and QT prolongation contribute to poor prognosis.
  • Cilnidipine, an L/N-type calcium channel blocker, may mitigate these risks.

Purpose of the Study:

  • To investigate cilnidipine's effects on heart rate and QT interval in hemodialysis patients.
  • To compare cilnidipine's efficacy against amlodipine in managing sympathetic nerve activity and QT prolongation.

Main Methods:

  • A 4-week amlodipine treatment was followed by a 4-week cilnidipine treatment.
  • Heart rate and corrected QT interval were measured on the final day of each treatment period.
  • Effects were compared between amlodipine and cilnidipine administration.

Main Results:

  • Cilnidipine demonstrated superior heart rate suppression during dialysis compared to amlodipine.
  • Amlodipine administration led to significant QT interval prolongation in some patients, an effect not observed with cilnidipine.

Conclusions:

  • Cilnidipine may effectively inhibit heart rate increases and QT interval prolongation in hemodialysis patients.
  • Cilnidipine holds potential for reducing cardiovascular events linked to sympathetic overactivity and arrhythmias.
Abstract

Keywords:
Cardiovascular eventHemodialysisHypertensionSudden deathSympathetic nerve activity

More Related Videos

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

3.9K
Preparation of Human Myocardial Tissue for Long-Term Cultivation10:58

Preparation of Human Myocardial Tissue for Long-Term Cultivation

Published on: June 2, 2022

5.8K

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.2K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.8K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.6K
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.9K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.6K